KORU Medical Q4 revenue up 60% to $6.5M, but full-year net loss widens to $4.6M

KORU Medical Systems, Inc.

Q4 net revenues $6.5M (+60% YoY); adjusted growth 27.6% excluding prior-year inventory stocking.
Full-year net loss $4.6M ($0.10 per share) vs $1.2M loss in 2020; adjusted EBITDA ($1.8M) vs $3.7M.
Ended 2021 with $25.3M cash; expects FY2022 revenue of $26-27M with gross margin exit run rate 60%.
Expanded label indications with three 510(k) clearances; announced strategic plan targeting $60M revenue by 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.